Serum Level of Endogenous Secretory Receptor for Advanced Glycation End Products and Other Factors in Type 2 Diabetic Patients with Mild Cognitive Impairment

Overview

Journal Diabetes Care

Specialty Endocrinology

Date 2011 Oct 21

PMID 22011410

Citations 20

Authors

Gang Chen

Liangchun Cai

Bin Chen

Jixing Liang

Fenhui Lin

Liantao Li

Lixiang Lin

Jin Yao

Junping Wen

Huibin Huang

Affiliations

Soon will be listed here.

Abstract

Objective: Determine the serum levels of endogenous secretory receptor for advanced glycation end products (esRAGEs) in patients with type 2 diabetes and mild cognitive impairment (MCI) and in control patients with type 2 diabetes but no MCI, and examine the relationship of esRAGE and MCI with other clinical factors.

Research Design And Methods: A total of 101 patients with type 2 diabetes who were hospitalized in the Department of Endocrinology at Fujian Provincial Hospital between January 2010 and January 2011 were enrolled. There were 58 patients with MCI and 43 patients without MCI (control). Serum levels of esRAGE were measured using an enzyme-linked immunosorbent assay (ELISA). Other clinical parameters were also measured.

Results: Type 2 diabetic patients with MCI had a longer duration of diabetes; elevated HbA(1c), total cholesterol (CHOL), LDL cholesterol (LDL-C), triglyceride (TG), intima-media thickness, C-reactive protein (CRP), and brachial-ankle pulse wave velocity (ba-PWV); and lower ankle brachial index (ABI) and esRAGE relative to the control group. Among patients with MCI, the Montreal Cognitive Assessment (MoCA) score was positively correlated with serum esRAGE but negatively correlated with CHOL. Spearman rank correlation analysis indicated that esRAGE was positively correlated with MoCA score and ABI but negatively correlated with ba-PWV, CHOL, TG, and CRP in all subjects.

Conclusions: Our results suggest that esRAGE may be a potential protective factor for dyslipidemia, atherosclerosis, and MCI in patients with type 2 diabetes.

Citing Articles

Quantifying Cognitive Function in Diabetes: Relationships Between AD8 Scores, HbA1c Levels, and Other Diabetic Comorbidities.

Chao H, Lin M, Fang T, Hsu M, Liang C, Lee M Biomedicines. 2025; 13(2).

PMID: 40002752 PMC: 11853454. DOI: 10.3390/biomedicines13020340.

Comparison of Eating Habits, Body Composition and Densitometric Parameters between Subjects with Normal Cognitive Function and Mild Cognitive Impairment: An Observational Study.

Jamka M, Chrobot M, Jaworska N, Brylak J, Makarewicz-Bukowska A, Popek J Nutrients. 2024; 16(5).

PMID: 38474772 PMC: 10934958. DOI: 10.3390/nu16050644.

The oDGal Mouse: A Novel, Physiologically Relevant Rodent Model of Sporadic Alzheimer's Disease.

Chadwick W, Maudsley S, Hull W, Havolli E, Boshoff E, Hill M Int J Mol Sci. 2023; 24(8).

PMID: 37108119 PMC: 10138655. DOI: 10.3390/ijms24086953.

Relationship between physical performance and mild cognitive impairment in elderly hemodialysis patients is modified by the presence of diabetes: A multicenter cross-sectional study.

Zhao Y, Song P, Zhu C, Zhang L, Chen X, Zhang H Front Endocrinol (Lausanne). 2022; 13:897728.

PMID: 36157461 PMC: 9501887. DOI: 10.3389/fendo.2022.897728.

Cognitive Function and Vitamin D Status in the Chinese Hemodialysis Patients.

Zhang J, Hu J, Zhou R, Xu Y Comput Math Methods Med. 2022; 2022:2175020.

PMID: 36118837 PMC: 9481383. DOI: 10.1155/2022/2175020.

References

Lindsey J, de Lemos J, Cipollone F, Ayers C, Rohatgi A, Morrow D . Association between circulating soluble receptor for advanced glycation end products and atherosclerosis: observations from the Dallas Heart Study. Diabetes Care. 2009; 32(7):1218-20. PMC: 2699719. DOI: 10.2337/dc09-0053. View

Panza F, Frisardi V, Seripa D, Imbimbo B, Sancarlo D, DOnofrio G . Metabolic syndrome, mild cognitive impairment, and dementia. Curr Alzheimer Res. 2011; 8(5):492-509. DOI: 10.2174/156720511796391818. View

Fan W, Parker R, Parpia B, Qu Y, Cassano P, Crawford M . Erythrocyte fatty acids, plasma lipids, and cardiovascular disease in rural China. Am J Clin Nutr. 1990; 52(6):1027-36. DOI: 10.1093/ajcn/52.6.1027. View

Pavlovic D, Pavlovic A . [Dementia and diabetes mellitus]. Srp Arh Celok Lek. 2008; 136(3-4):170-5. DOI: 10.2298/sarh0804170p. View

Logroscino G, Kang J, Grodstein F . Prospective study of type 2 diabetes and cognitive decline in women aged 70-81 years. BMJ. 2004; 328(7439):548. PMC: 381043. DOI: 10.1136/bmj.37977.495729.EE. View

Blasko I, Grubeck-Loebenstein B . Role of the immune system in the pathogenesis, prevention and treatment of Alzheimer's disease. Drugs Aging. 2003; 20(2):101-13. DOI: 10.2165/00002512-200320020-00002. View

Portet F, Ousset P, Visser P, Frisoni G, Nobili F, Scheltens P . Mild cognitive impairment (MCI) in medical practice: a critical review of the concept and new diagnostic procedure. Report of the MCI Working Group of the European Consortium on Alzheimer's Disease. J Neurol Neurosurg Psychiatry. 2006; 77(6):714-8. PMC: 2077456. DOI: 10.1136/jnnp.2005.085332. View

Colhoun H, Betteridge D, Durrington P, Hitman G, Neil A, Livingstone S . Total soluble and endogenous secretory receptor for advanced glycation end products as predictive biomarkers of coronary heart disease risk in patients with type 2 diabetes: an analysis from the CARDS trial. Diabetes. 2011; 60(9):2379-85. PMC: 3161327. DOI: 10.2337/db11-0291. View

Lue L, Yan S, STERN D, Walker D . Preventing activation of receptor for advanced glycation endproducts in Alzheimer's disease. Curr Drug Targets CNS Neurol Disord. 2005; 4(3):249-66. DOI: 10.2174/1568007054038210. View

10.

Hanon O, Haulon S, Lenoir H, Seux M, Rigaud A, Safar M . Relationship between arterial stiffness and cognitive function in elderly subjects with complaints of memory loss. Stroke. 2005; 36(10):2193-7. DOI: 10.1161/01.STR.0000181771.82518.1c. View

11.

Koyama H, Shoji T, Yokoyama H, Motoyama K, Mori K, Fukumoto S . Plasma level of endogenous secretory RAGE is associated with components of the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol. 2005; 25(12):2587-93. DOI: 10.1161/01.ATV.0000190660.32863.cd. View

12.

Santilli F, Vazzana N, Bucciarelli L, Davi G . Soluble forms of RAGE in human diseases: clinical and therapeutical implications. Curr Med Chem. 2009; 16(8):940-52. DOI: 10.2174/092986709787581888. View

13.

Ryan C, Geckle M . Why is learning and memory dysfunction in Type 2 diabetes limited to older adults?. Diabetes Metab Res Rev. 2000; 16(5):308-15. DOI: 10.1002/1520-7560(2000)9999:9999<::aid-dmrr141>3.0.co;2-x. View

14.

Velayudhan L, Poppe M, Archer N, Proitsi P, Brown R, Lovestone S . Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry. 2010; 196(1):36-40. DOI: 10.1192/bjp.bp.109.067942. View

15.

Yan S, Ramasamy R, Schmidt A . Soluble RAGE: therapy and biomarker in unraveling the RAGE axis in chronic disease and aging. Biochem Pharmacol. 2010; 79(10):1379-86. PMC: 2854502. DOI: 10.1016/j.bcp.2010.01.013. View

16.

An X, Zhao Y, Yu J, Liu J, Gu W, Gao F . Plasma sRAGE is independently associated with high sensitivity C-reactive protein in type 2 diabetes without coronary artery disease. Diabetes Res Clin Pract. 2009; 87(3):e19-22. DOI: 10.1016/j.diabres.2009.12.005. View

17.

Korf E, White L, Scheltens P, Launer L . Brain aging in very old men with type 2 diabetes: the Honolulu-Asia Aging Study. Diabetes Care. 2006; 29(10):2268-74. DOI: 10.2337/dc06-0243. View

18.

Petersen R, Roberts R, Knopman D, Boeve B, Geda Y, Ivnik R . Mild cognitive impairment: ten years later. Arch Neurol. 2009; 66(12):1447-55. PMC: 3081688. DOI: 10.1001/archneurol.2009.266. View

19.

Rafnsson S, Deary I, Fowkes F . Peripheral arterial disease and cognitive function. Vasc Med. 2009; 14(1):51-61. DOI: 10.1177/1358863X08095027. View

20.

Nozaki I, Watanabe T, Kawaguchi M, Akatsu H, Tsuneyama K, Yamamoto Y . Reduced expression of endogenous secretory receptor for advanced glycation endproducts in hippocampal neurons of Alzheimer's disease brains. Arch Histol Cytol. 2008; 70(5):279-90. DOI: 10.1679/aohc.70.279. View